Baylinson Ilene R.
Known title: General Mgr - Health & HumanCIK: 0001791080
Associated companies
Transaction History
| MMS | ▼ Sell | Tax Withholding | 3,945 | $210K | 9/30/2026 | View on chart |
| MMS | ▲ Buy | Grant | 7,647 | $0 | 12/2/2025 | View on chart |
| MMS | ▼ Sell | Tax Withholding | 3,831 | $331K | 12/2/2025 | View on chart |
| MMS | ▲ Buy | Grant | 28 | $0 | 12/1/2025 | View on chart |
| MMS | ▲ Buy | Grant | 7,409 | $0 | 11/24/2025 | View on chart |
| MMS | ▼ Sell | Tax Withholding | 3,623 | $331K | 9/30/2025 | View on chart |
| MMS | ▼ Sell | Open Market | 14,500 | $988K | 2/19/2025 | View on chart |
| MMS | ▼ Sell | Tax Withholding | 2,592 | $192K | 12/2/2024 | View on chart |
| MMS | ▲ Buy | Grant | 5,172 | $0 | 12/2/2024 | View on chart |
| MMS | ▼ Sell | Tax Withholding | 4,924 | $459K | 9/30/2024 | View on chart |
| MMS | ▼ Sell | Open Market | 10,043 | $859K | 12/12/2023 | View on chart |
| MMS | ▼ Sell | Open Market | 12 | $1K | 11/30/2023 | View on chart |
| MMS | ▼ Sell | Tax Withholding | 2,681 | $221K | 11/17/2023 | View on chart |
| MMS | ▲ Buy | Grant | 5,349 | $0 | 11/17/2023 | View on chart |
| MMS | ▼ Sell | Open Market | 7,073 | $528K | 9/29/2023 | View on chart |
| MMS | ▼ Sell | Open Market | 9,550 | $790K | 2/10/2023 | View on chart |
| MMS | ▼ Sell | Open Market | 5,783 | $335K | 9/30/2022 | View on chart |
| MMS | ▼ Sell | Open Market | 9,681 | $787K | 11/19/2021 | View on chart |
| MMS | ▼ Sell | Open Market | 8,116 | $675K | 9/30/2021 | View on chart |
| MMS | ▼ Sell | Open Market | 8,672 | $611K | 12/10/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Maximus Shifts Earnings Focus to Defense and Medicaid
Maximus is moving its earnings mix away from VA incentives toward defense and Medicaid contracts, as discussed in a recent Yahoo article. A ChartMill piece highlighted the company’s strong cash flow and low valuation. The Q3 2026 earnings call transcript provides further detail on the company’s strategy. These developments give insight into Maximus’s future revenue mix.
Maximus Shifts Earnings Focus to Defense and Medicaid. Maximus is moving its earnings mix away from VA incentives toward defense and Medicaid contracts, as discussed in a recent Yahoo article. A ChartMill piece highlighted the company’s strong cash flow and low valuation. The Q3 2026 earnings call transcript provides further detail on the company’s strategy. These developments give insight into Maximus’s future revenue mix.